Celularity and MuseCell Innovations established domestic manufacturing of Dezawa MuseCells — cells derived from perinatal tissue, bone marrow, or adipose sources — at a New Jersey facility. This production infrastructure supports both the parent cells and their derived products (exosomes and secretome), advancing clinical translation of a cell therapy platform with substantial preclinical validation.
Key Points
- U.S. manufacturing established for Dezawa MuseCells and derived products
- Cells sourced from perinatal tissue, bone marrow, and adipose depots
- 170+ peer-reviewed publications document MuseCell biology and mechanisms
Longevity Analysis
Cell therapies targeting regeneration and immune modulation represent a distinct approach to addressing age-related tissue decline and dysfunction. The manufacturing scale-up signals movement toward clinical implementation of a platform with established biological characterization. MuseCells are understood to operate through paracrine mechanisms—their secreted factors and extracellular vesicles—rather than direct cellular integration, which simplifies manufacturing, quality control, and regulatory pathways compared to integrating cell therapies. Establishing domestic GMP production removes supply-chain constraints and positions these tools for systematic investigation in tissue repair, immune dysregulation, and chronic inflammatory states that accelerate aging.
Original published by Longevity.Technology.